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Abstract
Background: In rodents, the development of dyskinesia produced by L-DOPA in the dopamine-depleted striatum occurs in
response to increased dopamine D1 receptor-mediated activation of the cAMP - protein kinase A and of the Ras-
extracellular signal-regulated kinase (ERK) signalling pathways. However, very little is known, in non-human primates, about
the regulation of these signalling cascades and their association with the induction, manifestation and/or maintenance of
dyskinesia.
Methodology/Results: We here studied, in the gold-standard non-human primate model of Parkinson’s disease, the
changes in PKA-dependent phosphorylation of DARPP-32 and GluR1 AMPA receptor, as well as in ERK and ribosomal
protein S6 (S6) phosphorylation, associated to acute and chronic administration of L-DOPA. Increased phosphorylation of
DARPP-32 and GluR1 was observed in both L-DOPA first-ever exposed and chronically-treated dyskinetic parkinsonian
monkeys. In contrast, phosphorylation of ERK and S6 was enhanced preferentially after acute L-DOPA administration and
decreased during the course of chronic treatment.
Conclusion: Dysregulation of cAMP signalling is maintained during the course of chronic L-DOPA administration, while
abnormal ERK signalling peaks during the initial phase of L-DOPA treatment and decreases following prolonged exposure.
While cAMP signalling enhancement is associated with dyskinesia, abnormal ERK signalling is associated with priming.
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Introduction
In Parkinson’s disease (PD), long-term treatment with L-3,4-
dihydroxyphenylalanine (L-DOPA) leads to the emergence of
dyskinesia, or involuntary aimless movements [1]. Work in rodents
has led to the identification of numerous changes in signalling
potentially implicated in L-DOPA-induced dyskinesis (LID) [2].
Prominent among these changes is a marked increase in the
dopamine D1 receptor (D1R)-mediated activation of (i) the
canonical adenylyl cyclase - protein kinase A (PKA) - dopamine
and cAMP-regulated phosphoprotein, 32 kDa (DARPP-32) sig-
nalling cascade [3,4] and (ii) the non-canonical Ras-extracellular
signal-regulated kinase (ERK) signalling cascade [5,6,7,8]. In
order to identify potential therapeutic targets, it is essential to
understand the role of these signalling cascades in the actual
induction, manifestation and/or maintenance of LID. However,
the correlation between abnormal PKA/DARPP-32 and Ras-
ERK signalling and severity of LID has been established only in
rodent models of LID and without the appropriate L-DOPA-
treated unlesioned controls. This limits a clear-cut association
between specific biochemical events and one or several of the
above mentioned key steps in LID elicitation.
In this study, we made use of the gold standard macaque model
of LIDs [3,9] to show that dysregulation of PKA/DARPP-32
signalling is mainly associated to the manifestation of dyskinesia,
while abnormal Ras-ERK signalling is most evident during the
development of this condition.
Materials and Methods
Animals
Thirty-nine F2-bred female rhesus monkeys (Macaca mulatta,
Xierxin, Beijing, PR of China; mean weight 5.360.8 kg; mean
age =561 years) were used. Animals were housed in individual
primate cages under controlled conditions of humidity (5065%),
temperature (2461uC) and light (12 h light/12 h dark cycles, time
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were carried out in accordance with European Communities
Council Directive of 24 November 1986 (86/609/EEC) for care of
laboratory animals in an AAALAC-accredited facility following
acceptance of study design by the Institute of Lab Animal Science
(Chinese Academy of Science, Beijing, China) IACUC. Veteri-
narians skilled in the healthcare and maintenance of non-human
primates supervised animal care. All reasonable efforts were made
to minimise animal suffering. The use of primates was minimised
by using an experimental design that permits statistically-
significant changes to be demonstrated with the smallest number
of animals per group and the smallest number of groups, consistent
with scientific rigour. Experiments followed previously published
procedures [3,11,12,13,14]. All animals were killed with a sodium
pentobarbital overdose (150 mg/kg, i.v.). Dissection of different
brain regions were performed on ice with the brain immersed in
cold saline (0.9%) in less than 15 min. The dorsolateral striatum
was dissected from each hemisphere, immediately frozen at
245uC in isopentane and then stored at 280uC.
Experimental Protocol
The experimental flowchart is described in figure 1. Six animals
were kept as untreated controls (control group), five received a
single dose of 20 mg/kg of L-DOPA p.o (control acute L-DOPA)
and five received 20 mg/kg of L-DOPA twice daily for three
months (control chronic L-DOPA). The remaining 32 animals
were treated daily (9:00 am) with 1-methyl-4-phenyl 1,2,3,6-
tetrahydropyridine (MPTP) hydrochloride (0.2 mg/kg, i.v., Sigma,
St Louis, MO) dissolved in saline according to a previously
described protocol [10]. Following stabilization of the MPTP-
induced syndrome, animals received saline (MPTP; n=5), a single
dose of 20 mg/kg of L-DOPA (MPTP acute L-DOPA; n=6), or
20 mg/kg of L-DOPA twice daily for three months (MPTP
chronic L-DOPA; n=12). Six animals developed severe and
reproducible dyskinesias, presenting choreic–athetoid (character-
ized by constant writhing and jerking motions), dystonic and
sometimes ballistic movements (large-amplitude flinging, flailing
movements) (MPTP-intoxicated and chronically L-DOPA-treated,
dyskinetic animal group), while 6 other did not (MPTP-intoxicated
and chronically L-DOPA-treated, non-dyskinetic animal group).
The MPTP intoxication protocol, the chronic L-DOPA treatment,
the clinical assessments, the terminal procedure and the charac-
terization of the extent of nigrostriatal denervation were conducted
as previously published [3,11,12,13,14]. DAT binding autoradi-
ography using [
125I]-(E)-N-(3-iodoprop-2-enyl)-2b-carboxymethyl-
3b-(49-methylphenyl)-nortropane; Chelatec, France) showed a
dramatic and similar reduction (.95%) in all MPTP-treated
groups in comparison to control animals, as published elsewhere
[12].
Behavioural assessment
Animal behaviour was assessed in their home cages. All
observers were blinded with regard to the experimental protocol.
During each session, two blinded examiners evaluated the level of
motor performance of each animal, by coaxing them to perform
various tasks by offering appetizing fruits. Animals received
supplemental feeding from day 7 onwards to maintain their body
weight as constant as possible. The degree of parkinsonism was
assessed daily (9 a.m.) for 30 min using a validated parkinsonian
macaque clinical scale [3,11,12,13,14] which rates the following
symptoms of parkinsonian disability: tremor, variations in the
general level of activity, body posture (flexion of spine),
vocalization, freezing and frequency of arm movements (reaching
for food for each upper limb) and rigidity (for each upper limb).
The minimal disability score was 0 and the maximum score was
25. The severity of dyskinesia was rated using the Dyskinesia
Disability Scale: 0, dyskinesia absent; 1, mild, fleeting, and rare
dyskinetic postures and movements; 2, moderate, more prominent
abnormal movements, but not interfering significantly with normal
behaviour; 3, marked, frequent and, at times, continuous
dyskinesia intruding on the normal repertoire of activity; or, 4,
severe, virtually continuous dyskinetic activity, disabling to the
Figure 1. Experimental flowchart illustrating study design, treatments and group assignments.
doi:10.1371/journal.pone.0012322.g001
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SEM were calculated daily for each group.
Western Blotting
Patches collected from 300 mm-thick fresh frozen coronal
sections containing dorsal motor putamen were sonicated in 1%
SDS and Western blotting was performed as described [6], using
antibodies against phospho-Thr34-DARPP-32 [15], phospho-
Ser845-GluR1 (PhosphoSolutions, Aurora, CO, USA), phospho-
Thr202/Tyr204-ERK1/2 and phospho-Ser235/236-S6 (Cell
Signaling Technology), and against total DARPP-32 [15], S6,
ERK and GluR1 (Cell Signaling Technology). Detection was
based on fluorescent secondary antibody binding and quantified
using a Li-Cor Odyssey infrared fluorescent detection system (Li-
Cor, Lincoln, NE). The levels of each phosphoprotein were
normalized for the amount of the corresponding total protein
detected in the sample.
Results
Parkinsonism and dyskinesia status
MPTP-treated animals displayed the classic progression of
symptoms previously shown with this intoxication regimen [10].
Monkeys became increasingly bradykinetic, adopted a stooped
posture, with increased rigidity of the limbs and decreased
vocalization. Movement accuracy progressively deteriorated and
there were occasional episodes of freezing as well as postural
tremor. Stable parkinsonism was obtained after 1960.5 MPTP
injections (parkinsonian score =9.360.34). All MPTP groups
displayed a similar parkinsonian score (MPTP: 8.560.5, MPTP
acute L-Dopa: 9.560.5, MPTP chronic L-Dopa (dyskinetic):
9.3360.4, MPTP chronic L-Dopa (non dyskinetic): 9.8360.87).
Parkinsonian scores of all MPTP groups were significantly
different from controls (F6,35 =88.12, p,0.0001) and identical
between them. Animals who developed L-Dopa induced dyskine-
sia following chronic L-Dopa treatment had a dyskinetic score of
2.3360.21.
cAMP signalling
Administration of L-DOPA, or MPTP-induced lesion, did not
alter, per se, the phosphorylation of DARPP-32 at Thr34 (Fig. 2A),
nor did they affect the phosphorylation of another PKA target, the
GluR1 subunit of the glutamate AMPA receptor (Fig. 2B). In
contrast, the first ever administration of L-DOPA to MPTP-
lesioned monkeys induced a trend toward increased phosphory-
lation of DARPP-32 at Thr34, and a significant increase in
phosphorylation of GluR1 at Ser845 (Fig. 2A–B). Following
chronic treatment with L-DOPA, the phosphorylation of DARPP-
Figure 2. Western blot analysis of levels of (A) phosphorylated DARPP-32 at Thr34, (B) phosphorylated GluR1 at Ser845, (C)
phosphorylatedERK1/2atThr202/Tyr204and(D)phosphorylated S6atSer235/Ser236inthedorsalputamen (mean±S.E.M.).Groups
were prepared as depicted in figure 1. Representative blots are shown above each panel. Data were analysed using a one-way ANOVA followed by post
hoc Tukey-Kramer multiple comparisons test (Graphpad Instat, Graphpad softwares, San Diego, CA). A probability level of 5%
(*: P,0.05)was considered statisticallysignificant. (A)F ( 6,37)=3.6, P=0.008; (B)F ( 6,42)=3.4, P=0.008; (C)F ( 6 , 38)=3.9, P=0.004; (D)F ( 6,38)=3.9, P=0.004.
doi:10.1371/journal.pone.0012322.g002
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dramatically increased in MPTP dyskinetic monkeys (Fig. 2A–B).
Enhanced DARPP-32 and GluR1 phosphorylation was also
detected in non-dyskinetic animals. However, these increases did
not reach statistical significance (Fig. 2A–B). Total levels of
DARPP-32 and GluR1 were unaffected by MPTP lesion and/or
treatment with L-DOPA (Fig. 2A–B). Thus, dopamine depletion is
accompanied by a considerable increase in dopamine D1 receptor
responsiveness at the postsynaptic level. This supports the idea of a
correlation between persistent activation of PKA signalling and
severity of LID.
ERK signalling
We next examined whether changes in phosphorylation of
ERK1/2 were associated with the first ever and/or the chronic L-
DOPA administration. Acute or chronic administration of L-
DOPA to control monkeys, as well as MPTP lesion per se, did not
affect ERK1/2 phosphorylation (Fig. 2C). L-DOPA produced a
large (4-fold) increase in phospho-ERK1/2, when given for the
first time ever to MPTP-lesioned monkeys (Fig. 2C). However, this
effect was reduced to a 2.5-fold increase over control after several
months of L-DOPA administration with no difference between
dyskinetic and non-dyskinetic monkeys (Fig. 2C).
Previous work showed that activated ERK phosphorylates S6 at
Ser235/236 and that this regulation promotes 59 cap-dependent
initiation of messenger RNA translation [17]. In the mouse,
increased S6 phosphorylation has been linked to ERK activation
and to the development of LID [18]. In our experiment, the
pattern of S6 phosphorylation at Ser235/236 in the various
experimental groups exactly matched that of phosphorylated ERK
(Fig. 2D). Total levels of ERK and S6 were unaffected by MPTP
lesion and/or treatment with L-DOPA (Fig. 3C–D).
Discussion
This study shows that, in a non-human primate model of
dyskinesia, the concomitant enhancement of cAMP and ERK
signalling in the dorsal striatum is associated to the induction of
LIDs. Moreover, once LIDs have been established, there is a
preponderant activation of the cAMP/DARPP-32 signalling
cascade associated to their acute manifestation.
Acute and chronic administration regimens of L-DOPA to
unlesioned monkeys do not affect the state of phosphorylation of
DARPP-32 and its target, GluR1. Similarly, L-DOPA per se does
not affect ERK and S6 phosphorylation. In contrast, after
dopamine denervation, the first ever administration of L-DOPA
activates both signalling cascades, as evidenced by the significant
Figure 3. Western blot analysis of levels of (A) DARPP-32 (B) GluR1 (C) ERK1/2 and (D) S6 in the dorsal putamen (mean ± S.E.M.).
Groups were prepared as depicted in Figure 1. Representative blots are shown above each panel.
doi:10.1371/journal.pone.0012322.g003
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Thr202/Tyr204-ERK and phospho-Ser235/Ser236–S6 (Fig. 2).
These changes in responsiveness are most likely attributable to
enhanced sensitivity of D1Rs, which has been described in rodent
[6,19] and non-human primate models [3], as well as in post-
mortem samples of parkinsonian patients [20].
The increase in phosphorylation of DARPP-32 and GluR1
produced by L-DOPA following MPTP-lesion is further increased
by chronic administration, but only in dyskinetic monkeys. These
results suggest that sensitized cAMP signalling plays a pivotal role
in the manifestation of dyskinesia. Moreover, they are in
agreement with data obtained in rodents, showing that the ability
of L-DOPA to increase DARPP-32 phosphorylation is preserved
in dyskinetic, but lost in non-dyskinetic animals [6,21].
The ability of L-DOPA to promote ERK signalling is maximal
at the first drug administration and declines during chronic
treatment. Thus, after three months of daily L-DOPA injections,
the phosphorylation of ERK1/2 and S6, albeit still enhanced, is
much closer to basal levels. The ability of prolonged administra-
tion to attenuate the effects of L-DOPA on ERK signalling has
been previously documented in the mouse [6]. However, studies in
rodent models show a correlation between LIDs and increased
ERK activation [5,6,7]. In contrast, the present data indicate that,
following prolonged L-DOPA administration, the levels of
phospho-Thr202/Tyr204-ERK and phospho-Ser235/236-S6
found in dyskinetic and non-dyskinetic monkeys are undistinguish-
able. This discrepancy may be explained by species difference, or
by the different length of exposure to chronic L-DOPA employed
in the two models (10 to 21 days in rodents vs. three months in
monkeys). Furthermore, as protein phosphorylation has here been
determined at the single time point of 60 min after administration
of L-DOPA, we cannot exclude that the effect of L-DOPA is
reduced to a rapid and transient increase in ERK signalling, which
cannot be detected under the present experimental conditions.
Nevertheless, even this type of change would indicate an extinction
of response, as a result of a prolonged administration of L-DOPA.
In conclusion, this study shows that, in non-human primates,
dopamine depletion confers to L-DOPA the ability to activate the
PKA/DARPP-32 and ERK cascades and that long-term (three
months) administration of L-DOPA leads to regression of ERK
activation, whereas cAMP/DARPP-32 signalling persists un-
changed, or even exacerbated. Given the involvement of ERK
and DARPP-32 in LIDs, as indicated by studies performed in
rodent models [5,6,7], these results are compatible with the
hypothesis that coordinated activation of cAMP/PKA/DARPP-
32 and ERK is implicated in the priming processes underlying the
emergence of dyskinesia. In this initial phase, activation of the Ras-
ERK signalling cascade would lead to transcriptional/translational
events necessary to produce and stabilize dyskinetic behaviour. In
a later phase, once LIDs have been established, hyper-activation of
PKA/DARPP-32 may become sufficient to maintain their
expression independently of ERK, most likely by short-term
regulation of neuronal activity through, for instance, regulation of
the state of phosphorylation of GluR1 and other ion channels.
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